A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis
2024 · Journal of the American Academy of Dermatology · 4 citations
https://doi.org/10.1016/j.jaad.2024.10.104